(Total Views: 494)
Posted On: 07/11/2020 4:11:18 PM
Post# of 11803
Wow.
That’s an interesting PR and pivot from Berman and DECN. I applaud the strategy.
As for the long term direction and potential M&A, that’s another sound and winning business strategy IMO. Value of any emerging bio-type company is at its highest after regulatory approval. Leverage in negotiation shifts to seller.
If it happens, I assume the repurchase of the diabetes platform would have Berman take the company private? That’s why most initially invested here and I continue to wait and hope for a low cost and effective solution for the diabetes afflicted; esp. younger children. This one is personal at my end.
So much going on you just can’t make this stuff up!
Make it happen, DECN!
That’s an interesting PR and pivot from Berman and DECN. I applaud the strategy.
As for the long term direction and potential M&A, that’s another sound and winning business strategy IMO. Value of any emerging bio-type company is at its highest after regulatory approval. Leverage in negotiation shifts to seller.
If it happens, I assume the repurchase of the diabetes platform would have Berman take the company private? That’s why most initially invested here and I continue to wait and hope for a low cost and effective solution for the diabetes afflicted; esp. younger children. This one is personal at my end.
So much going on you just can’t make this stuff up!
Make it happen, DECN!
(3)
(0)
